New computational method reduces risk of drug formulation

One major factor that determines the efficacy of a drug is the structure that its molecules form in a solid state. Changed molecular structures can entail that pills stop functioning properly and are therefore rendered useless. A team led by researchers from the University of Luxembourg in collaboration with Princeton University, Cornell University, and Avant-garde Materials Simulation GmbH, has developed a new method to calculate and predict how drug molecules in molecular crystals arrange themselves under changing energetic conditions. For pharmaceutical companies, this approach could be used to avoid expensive development failures, production errors, and potential litigation.

As the majority of drugs is marketed in a solid state, for example as pills, manufacturers have to make sure that they function properly and release the pharmaceutical agents in the required dose. "In the past, there have been several scandals in the pharmaceutical industry, when companies had identified a molecule that works, marketed it, and then, sometimes years later, due to minor changes in production conditions, the drug formulation stopped being effective," explains Prof. Alexandre Tkatchenko from the from the Physics and Materials Science Research Unit at the University of Luxembourg, the leading author of the resulting paper that was published in Science Advances. Consequently, some drugs needed to be reformulated and taken off the market for a long period of time.

In most cases, the reason for these changed properties lies in the interactions between the molecules. In a solid state, molecules organize in crystalline structures stabilized by a variety of intermolecular interactions. As molecules are very flexible, they can form many different arrangements with differing physical and chemical properties. "In order to predict this, pharma companies usually rely on 'trial and error' in crystallization experiments. However, realistically you can't study all possible forms experimentally, because you never know what will change in experimental conditions. The possibilities are exponential," explains Prof. Robert DiStasio, a co-author of the study from Cornell University.

In order to be able to replace these experiments with predictive calculations, the researchers teamed up with the company Avantgarde Materials Simulation that provides services for pharma companies to predict crystal structures of organic solids. Together, they developed a method that enables them to calculate how the energy of different solids changes depending on their structure. "The new approach improves the energy ranking accuracy at acceptable computational cost. It will change the way how crystal structure prediction is used throughout the pharmaceutical industry," comments Dr. Marcus Neumann, founder and CEO of Avant-garde Materials Simulation GmbH.

For the future, the authors plan to further develop the method and combine it with machine learning in order to increase the computational efficiency.

Johannes Hoja, Hsin-Yu Ko, Marcus A Neumann, Roberto Car, Robert A DiStasio Jr, Alexandre Tkatchenko.
Reliable and practical computational description of molecular crystal polymorphs.
Science Advances 11 Jan 2019: Vol. 5, no. 1. doi: 10.1126/sciadv.aau3338.

Most Popular Now

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Amgen and UCB receive positive vote from FDA Advis…

Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advis...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

Cannabinoid compounds may inhibit growth of colon …

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine resear...

Researchers call for big data infrastructure to su…

Researchers from the George Washington University (GW), the U.S. Food and Drug Administration (FDA), and industry leaders published in PLOS Biology, describing a standard...

New computational method reduces risk of drug form…

One major factor that determines the efficacy of a drug is the structure that its molecules form in a solid state. Changed molecular structures can entail that pills stop...